VEGFR-2/P-gp-IN-1

VEGFR-2/P-gp-IN-1 是一种 Licochalcone A (MS-G44558) 衍生物,也是一种具口服活性的 VEGFR-2 (IC50 = 0.885 μM) 和 P-糖蛋白 (P-gp) 抑制剂,通过同步抑制 VEGFR-2 激酶活性和 P-gp 药物外排泵功能,实现抗肿瘤增殖并克服化疗耐药性,同时可抑制 VEGFR-2 以及下游 PI3K/AKT 信号通路蛋白的磷酸化,诱导细胞凋亡 (Apoptosis),将细胞阻滞在 S 期,并抑制侵袭性迁移,在 HeLa/DDP 细胞异种移植瘤模型中展现出强大的体内抗肿瘤作用,可用于宫颈癌的研究。
VEGFR-2/P-gp-IN-1
产品编号: MS-Q64097 分子式: C24H24F6N2O3 分子量: 502.45
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

VEGFR-2/P-gp-IN-1 是一种 Licochalcone A (MS-G44558) 衍生物,也是一种具口服活性的 VEGFR-2 (IC50 = 0.885 μM) 和 P-糖蛋白 (P-gp) 抑制剂,通过同步抑制 VEGFR-2 激酶活性和 P-gp 药物外排泵功能,实现抗肿瘤增殖并克服化疗耐药性,同时可抑制 VEGFR-2 以及下游 PI3K/AKT 信号通路蛋白的磷酸化,诱导细胞凋亡 (Apoptosis),将细胞阻滞在 S 期,并抑制侵袭性迁移,在 HeLa/DDP 细胞异种移植瘤模型中展现出强大的体内抗肿瘤作用,可用于宫颈癌的研究。

生物实验数据

生物活性 VEGFR-2/P-gp-IN-1 is a Licochalcone A (MS-G44558) derivative and an orally active inhibitor of VEGFR-2 (IC50 = 0.885 μM) and P-glycoprotein (P-gp) that simultaneously inhibits VEGFR-2 kinase activity and P-gp drug efflux pump function to achieve antitumor proliferation and overcome chemoresistance, inhibits phosphorylation of VEGFR-2 and downstream PI3K/AKT signaling pathway proteins, induces apoptosis, arrests cells in S phase, and suppresses invasive migration, exhibits potent in vivo antitumor efficacy in a HeLa/DDP cell xenograft tumor model, and can be used for the study of cervical cancer.
体外研究
(In Vitro)

VEGFR-2/P-gp-IN-1 (Compound A20) (1-100 μM, 48 h) 显著抑制宫颈癌细胞 (含耐药株) 的增殖。

VEGFR-2/P-gp-IN-1 (1-6 μM, 24 h) 通过双重靶向抑制 VEGFR-2 磷酸化与 P-gp 外排功能,克服宫颈癌耐药性。

VEGFR-2/P-gp-IN-1 (1-4 μM,24 h) 在 HeLa/DDP 细胞系中通过激活细胞凋亡途径杀死癌细胞,在 S 期阻断细胞周期进程以抑制增殖,并显著抑制癌细胞的侵袭和迁移。

Western Blot Analysis

Cell Line: HeLa-DDP cells, HUVEC cells
Concentration: 1 μM, 2 μM, 4 μM, 6μM
Incubation Time: 24 h
Result: Dose-dependently inhibited VEGFR-2 and downstream PI3K/AKT phosphorylation.
Upregulated the pro-apoptotic protein Bax, downregulated the anti-apoptotic protein Bcl-2, and did not alter the expression level of P-gp protein.

Cell Viability Assay

Cell Line: HeLa/DDP drugresistant cells, HeLa/PTX drugresistant cells, HeLa/ADR drugresistant cells
Concentration: 1.0 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM
Incubation Time: 48 h
Result: Showed the most significant inhibitory activity against these three drug-resistant cervical cancer cell lines, with IC50 values of 3.69 μM (HeLa/DDP), 4.81 μM (HeLa/PTX), and 5.98 μM (HeLa/ADR), compared with HeLa cells, the resistance indices (RIs) were 1.16, 1.51, and 1.87, respectively.

Apoptosis Analysis

Cell Line: HeLa/DDP cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Induced apoptosis in HeLa cells at a rate of 92.3% at a concentration of 4 μM.
Induced apoptosis in HeLa/DDP cells at a rate of 94.5% at a concentration of 4 μM.

Cell Cycle Analysis

Cell Line: HeLa/DDP cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Induced S-phase arrest in HeLa cells at 39.32% at a concentration of 4 μM.
Induced S-phase arrest in HeLa/DDP cells at 39.04% at a concentration of 4 μM.

Immunofluorescence

Cell Line: HeLa/DDP cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Reduced the fluorescence intensity of p-VEGFR-2 in HeLa/HeLa-DDP cells in a dose-dependent manner.

Cell Invasion Assay

Cell Line: HeLa/DDP cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Reduced invasive potential of HeLa/DDP cells to 209, 142, and 54 cells at concentrations of 1, 2, and 4 μM.
Reduced invasive potential of HeLa cells to 360, 219, and 106 cells at concentrations of 1, 2, and 4 μM.

Cell Migration Assay

Cell Line: HeLa/DDP cells
Concentration: 1 μM, 2 μM, 4 μM
Incubation Time: 24 h
Result: Reduced penetration capacity of HeLa/DDP cells into the ventricular membrane to 268, 178, and 85 cells at concentrations of 1, 2, and 4 μM, respectively.
Reduced penetration capacity of HeLa cells through the ventricular membrane to 583, 286, and 226 cells at concentrations of 1, 2, and 4 μM.
体内研究
(In Vivo)

VEGFR-2/P-gp-IN-1 (Compound A20) (10 mg/kg, 20 mg/kg, 40 mg/kg, i.g., 每日一次, 持续 14 天) 在 HeLa/DDP 细胞异种移植小鼠模型中显示出治疗顺铂耐药性宫颈癌的潜力,且安全性良好,未表现显著毒性。

Animal Model: HeLa/DDP cell xenograft model established in BALB/C nude female mice (4-5 weeks)
Dosage: 10 mg/kg, 20 mg/kg, 40 mg/kg
Administration: Daily intragastric gavage (i.g.), at the corresponding doses for 14 days.
Result: Suppressed grafted tumors by 70.9%, 72.2%, and 89.5% at doses of 10, 20, and 40 mg/kg (positive control sorafenib 20 mg/kg: 36.1% reduction).
Inhibited growth of drug-resistant cervical cancer xenografts dose-dependently via oral administration.
Maintained comparable body weight across all groups.
Animal Model: Female Kunming mice (5 weeks, 20-22 g)
Dosage: 200 mg/kg
Administration: Daily intragastric gavage (i.g.), at the corresponding doses for 14 days.
Result: Caused no mortality or significant body weight changes versus controls in acute mouse toxicity testing.
Induced normal liver/kidney function without necrosis, structural disorder, or inflammatory infiltration in acute mouse toxicity testing.
Demonstrated safety at 200 mg/kg without significant toxicity.

化学信息

分子量 502.45
分子式 C24H24F6N2O3

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础